Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2017, Article ID 6730812, 8 pages
https://doi.org/10.1155/2017/6730812
Research Article

Incidence and Risk Factors for Infections Requiring Hospitalization, Including Pneumocystis Pneumonia, in Japanese Patients with Rheumatoid Arthritis

1Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan
2Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan
3Department of Clinical Laboratory, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan
4Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Correspondence should be addressed to Atsushi Hashimoto; pj.rg.psoh-arahimagas@otomihsah-a

Received 11 June 2017; Revised 23 August 2017; Accepted 17 September 2017; Published 18 October 2017

Academic Editor: Bruce M. Rothschild

Copyright © 2017 Atsushi Hashimoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. F. Doran, C. S. Crowson, G. R. Pond, W. M. O'Fallon, and S. E. Gabriel, “Frequency of infection in patients with rheumatoid arthritis compared with controls: A Population-Based Study,” Arthritis & Rheumatology, vol. 46, no. 9, pp. 2287–2293, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Shinomiya, N. Mima, K. Nanba et al., “Life expectancies of Japanese patients with rheumatoid arthritis: A review of deaths over a 20-year period,” Modern Rheumatology, vol. 18, no. 2, pp. 165–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Nakajima, E. Inoue, E. Tanaka et al., “Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA,” Scandinavian Journal of Rheumatology, vol. 39, no. 5, pp. 360–367, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. F. Thomas Jr. and A. H. Limper, “Pneumocystis pneumonia,” The New England Journal of Medicine, vol. 350, no. 24, pp. 2487–2498, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Tokuda, F. Sakai, H. Yamada et al., “Clinical and radiological features of pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and pneumocystis pneumonia in acquired immunodeficiency syndrome: A multicenter study,” Internal Medicine, vol. 47, no. 10, pp. 915–923, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis & Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Aletaha, T. Neogi, A. J. Silman et al., “2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” Arthritis & Rheumatology, vol. 62, no. 9, pp. 2569–2581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Steinbrocker, C. H. Traeger, and R. C. Batterman, “Therapeutic criteria in rheumatoid arthritis,” The Journal of the American Medical Association, vol. 140, no. 8, pp. 659–662, 1949. View at Publisher · View at Google Scholar · View at Scopus
  9. M. C. Hochberg, R. W. Chang, I. Dwosh, S. Lindsey, T. Pincus, and F. Wolfe, “The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 35, no. 5, pp. 498–502, 1992. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Matsuo, E. Imai, M. Horio et al., “Revised equations for estimated GFR from serum creatinine in Japan,” American Journal of Kidney Diseases, vol. 53, no. 6, pp. 982–992, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Tasaka, N. Hasegawa, S. Kobayashi et al., “Serum indicators for the diagnosis of pneumocystis pneumonia,” CHEST, vol. 131, no. 4, pp. 1173–1180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Katsuyama, K. Saito, S. Kubo, M. Nawata, and Y. Tanaka, “Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study,” Arthritis Research & Therapy, vol. 16, no. 1, article R43, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Hashimoto, N. Chiba, H. Tsuno et al., “Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population,” The Journal of Rheumatology, vol. 42, no. 4, pp. 564–571, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. A. L. Smitten, H. K. Choi, M. C. Hochberg et al., “The risk of hospitalized infection in patients with rheumatoid arthritis,” The Journal of Rheumatology, vol. 35, no. 3, pp. 387–393, 2008. View at Google Scholar · View at Scopus
  15. K. Au, G. Reed, J. R. Curtis et al., “High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 5, pp. 785–791, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Komano, M. Tanaka, T. Nanki et al., “Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: A report from the registry of Japanese rheumatoid arthritis patients for longterm safety,” The Journal of Rheumatology, vol. 38, no. 7, pp. 1258–1264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. C. S. Crowson, D. D. Hoganson, P. D. Fitz-Gibbon, and E. L. Matteson, “Development and validation of a risk score for serious infection in patients with rheumatoid arthritis,” Arthritis & Rheumatology, vol. 64, no. 9, pp. 2847–2855, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Sakai, Y. Komano, M. Tanaka et al., “Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis,” Arthritis Care & Research, vol. 64, no. 8, pp. 1125–1134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. O. M. Ni Mhuircheartaigh, E. L. Matteson, A. B. Green, and C. S. Crowson, “Trends in serious infections in rheumatoid arthritis,” The Journal of Rheumatology, vol. 40, no. 5, pp. 611–616, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. A. Singh, C. Cameron, S. Noorbaloochi et al., “Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis,” The Lancet, vol. 386, no. 9990, pp. 258–265, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Widdifield, S. Bernatsky, J. M. Paterson et al., “Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis.,” Arthritis care & research, vol. 65, no. 3, pp. 353–361, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Yun, F. Xie, E. Delzell et al., “Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare,” Arthritis & Rheumatology, vol. 68, no. 1, pp. 56–66, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Listing, K. Gerhold, and A. Zink, “The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment,” Rheumatology, vol. 52, no. 1, Article ID kes305, pp. 53–61, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Baum, “Infection in Rheumatoid Arthritis,” Arthritis & Rheumatism, vol. 14, no. 1, pp. 135–137, 1971. View at Publisher · View at Google Scholar · View at Scopus
  25. I. S. Kourbeti, P. D. Ziakas, and E. Mylonakis, “Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: A meta-analysis,” Clinical Infectious Diseases, vol. 58, no. 12, pp. 1649–1657, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. J. P. Leombruno, T. R. Einarson, and E. C. Keystone, “The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events,” Annals of the Rheumatic Diseases, vol. 68, no. 7, pp. 1136–1145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. D. Greenberg, G. Reed, J. M. Kremer et al., “Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry,” Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 380–386, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. M. F. Doran, C. S. Crowson, G. R. Pond, W. M. O'Fallon, and S. E. Gabriel, “Predictors of infection in rheumatoid arthritis,” Arthritis & Rheumatology, vol. 46, no. 9, pp. 2294–2300, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Sakai, Y. Komano, M. Tanaka et al., “The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis,” Modern Rheumatology, vol. 21, no. 4, pp. 444–448, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. K. J. Aaltonen, J. T. Joensuu, L. Virkki et al., “Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy,” The Journal of Rheumatology, vol. 42, no. 3, pp. 372–378, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. A. McLean-Tooke, C. Aldridge, S. Waugh, G. P. Spickett, and L. Kay, “Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?” Rheumatology, vol. 48, no. 8, pp. 867–871, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Iikuni, M. Kitahama, S. Ohta, H. Okamoto, N. Kamatani, and M. Nishinarita, “Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease,” Modern Rheumatology, vol. 16, no. 5, pp. 282–288, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Tanaka, R. Sakai, R. Koike et al., “Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: A retrospective review of 15 cases and analysis of risk factors,” Modern Rheumatology, vol. 22, no. 6, pp. 849–858, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Komano, M. Harigai, and R. Koike, “Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients,” Arthritis & Rheumatology, vol. 61, no. 3, pp. 305–12, 2009. View at Publisher · View at Google Scholar
  35. P. M. Houtman, A. A. Stenger, G. A. Bruyn, and J. Mulder, “Methotrexate may affect certain T lymphocyte subsets in rheumatoid arthritis resulting in susceptibility to Pneumocystis carinii infection,” Journal of Rheumatology, vol. 21, no. 6, pp. 1168–1170, 1994. View at Google Scholar
  36. Y. Li, M. Ghannoum, C. Deng et al., “Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases: Usefulness of lymphocyte subtyping,” International Journal of Infectious Diseases, vol. 57, pp. 108–115, 2017. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Mori and M. Sugimoto, “Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis,” Rheumatology, vol. 51, no. 12, Article ID kes244, pp. 2120–2130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Mimori, M. Harigai, T. Atsumi et al., “Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan,” Modern Rheumatology, pp. 1–11, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. G. H. Louie, Z. Wang, and M. M. Ward, “Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996-2007,” Arthritis & Rheumatology, vol. 62, no. 12, pp. 3826-3827, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. E. S. Bruce, L. Kearsley-Fleet, K. D. Watson, and etal., “Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the british society for rheumatology Biologics Register for Rheumatoid Arthritis,” Rheumatology, vol. 55, no. 7, pp. 1336-1337, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Watanabe, R. Sakai, R. Koike et al., “Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: A retrospective review and case-control study of 17 patients,” Modern Rheumatology, vol. 23, no. 6, pp. 1085–1093, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Harigai, R. Koike, and N. Miyasaka, “Pneumocystis pneumonia associated with infliximab in Japan,” The New England Journal of Medicine, vol. 357, no. 18, pp. 1874–1876, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Mori, I. Cho, H. Ichiyasu, and M. Sugimoto, “Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan: A possible association between colonization and development of Pneumocystis jiroveci pneumonia during low-dose MTX therapy,” Modern Rheumatology, vol. 18, no. 3, pp. 240–246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Fritzsche, D. Riebold, A. K. Munk-Hartig, S. Klammt, G. Neeck, and E. C. Reisinger, “High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy,” Scandinavian Journal of Rheumatology, vol. 41, no. 3, pp. 208–213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. N. A. Maskell, D. J. Waine, A. Lindley et al., “Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: A prospective study,” Thorax, vol. 58, no. 7, pp. 594–597, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Wissmann, R. Morilla, I. Martín-Garrido et al., “Pneumocystis jirovecii colonization in patients treated with infliximab,” European Journal of Clinical Investigation, vol. 41, no. 3, pp. 343–348, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Vidal, C. de la Horra, J. Martín et al., “Pneumocystis jirovecii colonisation in patients with interstitial lung disease,” Clinical Microbiology and Infection, vol. 12, no. 3, pp. 231–235, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. E. J. Calderón, L. Rivero, N. Respaldiza et al., “Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci.,” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 45, no. 2, pp. e17–19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Mori, I. Cho, and M. Sugimoto, “A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis,” The Journal of Rheumatology, vol. 36, no. 8, pp. 1600–1605, 2009. View at Publisher · View at Google Scholar · View at Scopus